Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
KURA

KURA - Kura Oncology Inc Stock Price, Fair Value and News

$8.03-0.44 (-5.19%)
Market Closed

54/100

KURA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

54/100

KURA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$8.79

Target 3M

$8.67

Target 6M

$8.71

KURA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KURA Price Action

Last 7 days

-7.9%

Last 30 days

-23.2%

Last 90 days

-23.1%

Trailing 12 Months

3.4%

KURA RSI Chart

KURA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KURA Valuation

Market Cap

698.8M

Price/Earnings (Trailing)

-3.22

Price/Sales (Trailing)

8.05

EV/EBITDA

-2.85

Price/Free Cashflow

8.41

KURA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$8.79

Target 3M

$8.67

Target 6M

$8.71

KURA Fundamentals

KURA Revenue

Revenue (TTM)

86.8M

Rev. Growth (Yr)

252.17%

Rev. Growth (Qtr)

35.73%

KURA Earnings

Earnings (TTM)

-216.9M

Earnings Growth (Yr)

-36.23%

Earnings Growth (Qtr)

-12.09%

KURA Profitability

EBT Margin

-247.17%

Return on Equity

-89.42%

Return on Assets

-33.4%

Free Cashflow Yield

11.89%

KURA Investor Care

Shares Dilution (1Y)

11.90%

Diluted EPS (TTM)

-2.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202562.0M72.0M86.8M0
202417.2M019.9M52.3M
20236.8M9.4M12.6M14.7M
20221.2M1.5M2.3M4.3M
20212.0M01.5M1.2M
20205.0M4.8M4.0M2.8M
20193.7M4.1M4.5M4.9M
20181.0M1.5M2.4M3.2M
2017780.0K709.0K711.0K784.5K
20161.2M1.1M990.0K885.0K
2015001.2M1.2M
20140000
Get all data in R, Python etc through our Historical Stock Data APIs

About Kura Oncology Inc

KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
 CEO
 WEBSITEhttps://kuraoncology.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES133

Kura Oncology Inc Frequently Asked Questions

KURA is the stock ticker symbol of Kura Oncology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Kura Oncology Inc is 698.75 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check KURA's fair value in chart for subscribers.

The fair value guage provides a quick view whether KURA is over valued or under valued. Whether Kura Oncology Inc is cheap or expensive depends on the assumptions which impact Kura Oncology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KURA.

As of Wed Jan 28 2026, KURA's PE ratio (Price to Earnings) is -3.22 and Price to Sales (PS) ratio is 8.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KURA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Kura Oncology Inc has provided 0.053 (multiply by 100 for percentage) rate of return.